Sirona Biochem launches anti-ageing preclinical studies with Biogalenys laboratory
Aims to use the data to optimise commercial applications for anti-ageing compounds
With funding from Bpifrance and the district of Haute Normandie, Canadian company Sirona Biochem's French subsidiary TFChem has moved into the next phase of its agreement with contract research organisation (CRO) Biogalenys, also a French company.
Biogalenys provides tests for active ingredients, chemical compounds and biological assays to the pharmaceutical and cosmetic industries.
The CRO designs the studies, conducts assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. The company will work with scientists at TFChem to develop studies on anti-ageing technology.
The research will provide preclinical data supporting multiple targeted applications using novel in-vitro tests with varying stress conditions and cell types. The aim is to validate the compounds and satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.
'We are excited to be launching this next phase of development with Biogalenys,' said Howard Verrico, CEO of Sirona Biochem.
'Our two companies previously worked together successfully on skin lightening technology and have maintained an excellent relationship of shared knowledge. The research on these anti-ageing compounds is exciting from both scientific discovery and commercial opportunity.'
Industry analysts predict that the anti-ageing market will reach nearly US$285bn by 2018.
